Agios Pharm

NASDAQ AGIO

Data sourced from

and

Download Data

Agios Pharm Capital Stock Change for the year ending December 31, 2023

Agios Pharm Capital Stock Change is NA for the year ending December 31, 2023. Capital Stock Change is the net change in the company's capital stock during a specific period, including the issuance or retirement of shares.

Agios Pharm Capital Stock Change for the year ending December 31, 2021 was USD 0.00, a 0.00% change year over year.
Agios Pharm Capital Stock Change for the year ending December 31, 2020 was USD 0.00, a -100.00% change year over year.
Agios Pharm Capital Stock Change for the year ending December 31, 2019 was USD 277.20 M, a -46.30% change year over year.

NASDAQ: AGIO

Agios Pharm

CEO	Dr. Bruce D. Car DACVP, Ph.D.
IPO Date	July 24, 2013
Location	United States
Headquarters	88 Sidney Street, Cambridge, MA, United States, 02139-4169
Employees	383
Sector	Healthcare
Industry	Biotechnology

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key trends